Stent Thrombosis

A meta-analysis of randomized controlled trials published in the Annals of Internal Medicine showed that dual therapy was associated with lower risk for major bleeding in patients with nonvalvular atrial fibrillation after PCI compared with triple therapy.

Patients who underwent coronary revascularization with a bioresorbable polymer sirolimus-eluting stent had significantly lower rates of target vessel MI, late/very late stent thrombosis and clinically driven target lesion revascularization compared with those who underwent the procedure with a durable polymer everolimus-eluting stent, according to 3-year data from the BIOFLOW V trial presented at Cardiovascular Research Technologies.

Among patients with ACS who underwent PCI and received an outpatient prescription for ticagrelor or clopidogrel, ticagrelor was not associated with a significant reduction in risk for MACE, and those who received ticagrelor had more major bleeding and dyspnea, according to data from a population-based cohort study published in JAMA Internal Medicine.

There were no significant differences for survival or other clinical endpoints at 30 days among patients with STEMI who underwent PCI via radial access compared with femoral access, according to results of the SAFARI-STEMI trial published in JAMA Cardiology.

Outcomes at 2 years were similar for patients who underwent PCI with a ridaforolimus-eluting stent compared with a zotarolimus-eluting stent, according to a pooled analysis of two randomized trials published in JACC: Cardiovascular Interventions.

Among patients who underwent PCI, those with cancer had elevated risks for cardiac mortality and bleeding, researchers reported in JACC: CardioOncology.

SAN FRANCISCO — Among patients with CAD in the left main artery who underwent PCI, a biodegradable polymer everolimus-eluting stent plus 4 months of dual antiplatelet therapy conferred similar outcomes as a durable polymer EES plus 1 year of DAPT, according to results from the IDEAL-LM trial.

SAN FRANCISCO — In the first randomized trial to compare a durable-polymer DES with a polymer-free drug-coated stent in patients with high bleeding risk who received 1 month of dual antiplatelet therapy, treatment with the DES was as safe and effective as treatment with the DCS, according to results of the Onyx ONE trial presented at TCT 2019.

PARIS — In patients with atrial fibrillation who underwent PCI, an antithrombotic strategy of edoxaban plus a P2Y12 inhibitor was noninferior to a vitamin K antagonist-based triple regimen for bleeding, with no significant differences in ischemic events.

PARIS — In patients with acute coronary syndromes, with or without ST-segment elevation, the rate of death, MI or stroke was significantly reduced at 1 year with prasugrel compared with ticagrelor, without an increase in major bleeding, according to a head-to-head comparison of both strategies.